Home
News
AbbVie's extension of indication application for epcoritamab in 3L r/r FL under EMA evaluation

AbbVie's extension of indication application for epcoritamab in 3L r/r FL under EMA evaluation

1 dicembre 2023 - Newsletter n. 45 - Dicembre 2023

Attenzione! Il presente contenuto è disponibile solo in lingua originale.

AbbVie has announced that the EMA has validated its extension of indication application for Tepkinly (epcoritamab) for the treatment of adult patients with R/R FL after two or more therapies.

This submission is supported by the results from the Phase 1/2 EPCORE NHL-1 clinical trial evaluating the safety and preliminary efficacy of subcutaneous epcoritamab in 128 adult patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including FL.

EPCORE NHL-1 is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab that consists of three parts: a Phase 1 first-in-human, dose escalation part; a Phase 2a expansion part; and a Phase 2a dose optimization part

Reference link: AbbVie press release

Tags: Tepkinly epcoritamab FL Follicular Lymphoma linfoma follicolare FL R/R

Come giudichi questo contenuto?

Utile Non utile

Grazie per il tuo feedback!

AbbVie's extension of indication application for epcoritamab in 3L r/r FL under EMA evaluation

Come giudichi questo contenuto?

epcoritamab: un nuovo anticorpo bispecifico first-in-class per il trattamento di pazienti con linfoma a grandi cellule B recidivante/refrattario

EMA: epcoritamab avvenuta la validazione pratica di richiesta AIC nel DLBCL r/r

FDA accorda la priority review per l'anticorpo bispecifico epcoritamab per il trattamento del linfoma a grandi cellule B recidivato/refrattario

FDA approves Epkinly (epcoritamab) injection treatment for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma

CHMP opinion positiva per Epcoritamab (Tepkinly) come monoterapia per il trattamento di pazienti adulti con linfoma diffuso a grandi cellule B recidivato o refrattario (R/R) (DLBCL) dopo due o più linee di terapia sistemica.

EMA Conditional Approval of AbbVie’s Tepkinly (epcoritamab) for R/R Diffuse Large B-cell Lymphoma (DLBCL)

AbbVie’s epcoritamab gets one step closer to follicular lymphoma approval by FDA

Iqirvo® (elafibranor) data shows efficacy and safety for up to 3 years in patients with PBC with improvements in fatigue and pruritus

Intercept announced receipt of a Complete Response Letter (CRL) from FDA for its Ocaliva

AstraZeneca and Daiichi Sankyo announced the voluntary withdrawal of the US application of Dato-DXd (TROP2 ADC) for 2L+ locally advanced or metastatic non-squamous (Nsq) lung cancer (NSCLC)